Atezolizumab Biosimilar, Human IgG4 S228P Mutant | Catalog C024P.4S

Atezolizumab Biosimilar, Human IgG4 S228P Mutant. The research grade Atezolizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Atezolizumab but not durvalumab binds and blocks mouse PD-L1.

Product Specifications

Catalog No.	C024P.4S
Product Name	Atezolizumab Biosimilar, Human IgG4 S228P Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	Produced in the atezolizumab biosimilar CHO stable cell line.
Specificity	Specifically binds to the human PDL1 protein.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab.

Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (N297A) in the heavy chain leading to minimized binding to FcγRs. It binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors.